{"/market-intelligence/indication-pipeline/": {"indication_pipeline": {"prurigo nodularis": [{"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "RUXOLITINIB", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1789941", "Type": "Small molecule", "Mechanism of Action": "Tyrosine-protein kinase JAK1 inhibitor", "Phase": "Phase 3", "Status": "Recruiting", "Target": "JAK1", "Target URL": "https://platform.opentargets.org/target/ENSG00000162434", "Source URLs": ["https://clinicaltrials.gov/study/NCT05764161"], "Sponsor": "Incyte Corporation", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT05764161": "A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NEMOLIZUMAB", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297794", "Type": "Antibody", "Mechanism of Action": "Interleukin-31 receptor subunit alpha inhibitor", "Phase": "Phase 3", "Status": "Completed", "Target": "IL31RA", "Target URL": "https://platform.opentargets.org/target/ENSG00000164509", "Source URLs": ["https://clinicaltrials.gov/study/NCT05052983", "https://clinicaltrials.gov/study/NCT04501666", "https://clinicaltrials.gov/study/NCT04501679"], "Sponsor": "Galderma R&amp;D", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT05052983": "A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis", "NCT04501666": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis", "NCT04501679": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NEMOLIZUMAB", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL4297794", "Type": "Antibody", "Mechanism of Action": "Interleukin-31 receptor subunit alpha inhibitor", "Phase": "Phase 3", "Status": "Active, not recruiting", "Target": "IL31RA", "Target URL": "https://platform.opentargets.org/target/ENSG00000164509", "Source URLs": ["https://clinicaltrials.gov/study/NCT04204616"], "Sponsor": "Galderma R&amp;D", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT04204616": "A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "RUXOLITINIB", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1789941", "Type": "Small molecule", "Mechanism of Action": "Tyrosine-protein kinase JAK2 inhibitor", "Phase": "Phase 3", "Status": "Recruiting", "Target": "JAK2", "Target URL": "https://platform.opentargets.org/target/ENSG00000096968", "Source URLs": ["https://clinicaltrials.gov/study/NCT05764161"], "Sponsor": "Incyte Corporation", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT05764161": "A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "DUPILUMAB", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL2108675", "Type": "Antibody", "Mechanism of Action": "Interleukin-4 receptor subunit alpha antagonist", "Phase": "Phase 3", "Status": "Recruiting", "Target": "IL4R", "Target URL": "https://platform.opentargets.org/target/ENSG00000077238", "Source URLs": ["https://clinicaltrials.gov/study/NCT06293053"], "Sponsor": "Sanofi", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT06293053": "A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants \u22656 Months to <18 Years of Age With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE HYDROCHLORIDE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201132", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRD1", "Target URL": "https://platform.opentargets.org/target/ENSG00000116329", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "SERLOPITANT", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL447955", "Type": "Small molecule", "Mechanism of Action": "Neurokinin 1 receptor antagonist", "Phase": "Phase 2", "Status": "Completed", "Target": "TACR1", "Target URL": "https://platform.opentargets.org/target/ENSG00000115353", "Source URLs": ["https://clinicaltrials.gov/study/NCT02196324"], "Sponsor": "Vyne Therapeutics Inc.", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT02196324": "A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL895", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRK1", "Target URL": "https://platform.opentargets.org/target/ENSG00000082556", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE HYDROCHLORIDE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201132", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRM1", "Target URL": "https://platform.opentargets.org/target/ENSG00000112038", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE HYDROCHLORIDE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1201132", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRK1", "Target URL": "https://platform.opentargets.org/target/ENSG00000082556", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "HYDROCORTISONE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL389621", "Type": "Small molecule", "Mechanism of Action": "Glucocorticoid receptor agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "NR3C1", "Target URL": "https://platform.opentargets.org/target/ENSG00000113580", "Source URLs": ["https://clinicaltrials.gov/study/NCT00507832"], "Sponsor": "University Hospital Muenster", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00507832": "Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "PIMECROLIMUS", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL1200686", "Type": "Small molecule", "Mechanism of Action": "FK506-binding protein 1A inhibitor", "Phase": "Phase 2", "Status": "Completed", "Target": "FKBP1A", "Target URL": "https://platform.opentargets.org/target/ENSG00000088832", "Source URLs": ["https://clinicaltrials.gov/study/NCT00507832"], "Sponsor": "University Hospital Muenster", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00507832": "Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL895", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRM1", "Target URL": "https://platform.opentargets.org/target/ENSG00000112038", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "APREMILAST", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800", "Type": "Small molecule", "Mechanism of Action": "Phosphodiesterase 4 inhibitor", "Phase": "Phase 2", "Status": "Completed", "Target": "PDE4A", "Target URL": "https://platform.opentargets.org/target/ENSG00000065989", "Source URLs": ["https://clinicaltrials.gov/study/NCT00869089"], "Sponsor": "University Hospitals Cleveland Medical Center", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00869089": "An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "APREMILAST", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800", "Type": "Small molecule", "Mechanism of Action": "Phosphodiesterase 4 inhibitor", "Phase": "Phase 2", "Status": "Completed", "Target": "PDE4B", "Target URL": "https://platform.opentargets.org/target/ENSG00000184588", "Source URLs": ["https://clinicaltrials.gov/study/NCT00869089"], "Sponsor": "University Hospitals Cleveland Medical Center", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00869089": "An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "APREMILAST", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800", "Type": "Small molecule", "Mechanism of Action": "Phosphodiesterase 4 inhibitor", "Phase": "Phase 2", "Status": "Completed", "Target": "PDE4C", "Target URL": "https://platform.opentargets.org/target/ENSG00000105650", "Source URLs": ["https://clinicaltrials.gov/study/NCT00869089"], "Sponsor": "University Hospitals Cleveland Medical Center", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00869089": "An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "NALBUPHINE", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL895", "Type": "Small molecule", "Mechanism of Action": "Opioid receptors; mu/kappa/delta agonist", "Phase": "Phase 2", "Status": "Completed", "Target": "OPRD1", "Target URL": "https://platform.opentargets.org/target/ENSG00000116329", "Source URLs": ["https://clinicaltrials.gov/study/NCT03497975"], "Sponsor": "Trevi Therapeutics", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT03497975": "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)"}, "PMIDs": [], "OutcomeStatus": "Not Known"}, {"Disease": "prurigo nodularis", "Disease URL": "https://platform.opentargets.org/disease/MONDO_0026045", "Drug": "APREMILAST", "Drug URL": "https://platform.opentargets.org/drug/CHEMBL514800", "Type": "Small molecule", "Mechanism of Action": "Phosphodiesterase 4 inhibitor", "Phase": "Phase 2", "Status": "Completed", "Target": "PDE4D", "Target URL": "https://platform.opentargets.org/target/ENSG00000113448", "Source URLs": ["https://clinicaltrials.gov/study/NCT00869089"], "Sponsor": "University Hospitals Cleveland Medical Center", "WhyStopped": "", "ApprovalStatus": "Not Known", "NctIdTitleMapping": {"NCT00869089": "An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis"}, "PMIDs": [], "OutcomeStatus": "Not Known"}]}}, "/evidence/network-biology/": {"results": []}}